Litcius/Paper detail

Fusogenic peptide delivery of bioactive siRNAs targeting CSNK2A1 for treatment of ovarian cancer

Timothy Samec, Kharimat Lora Alatise, Jessica Boulos, Serena Gilmore, Anthony Hazelton, Carleigh Coffin, Angela Alexander-Bryant

2022Molecular Therapy — Nucleic Acids19 citationsDOIOpen Access PDF

Abstract

. Intratumoral delivery of DIV3W-siCSNK2A1 complexes to subcutaneous ovarian tumors resulted in reduced CSNK2A1 mRNA and CK2α protein expression after 48 h and reduced tumor growth and migration in a 2-week multi-dosing regimen. These results demonstrate the potential of the DIV3W peptide to deliver bioactive siRNAs and confirms the role of CSNK2A1 in cell-cell communication and proliferation in ovarian cancer.

Topics & Concepts

Small interfering RNAOvarian cancerGene knockdownCancer researchCancerCancer cellBiologyMedicinePharmacologyInternal medicineApoptosisCell cultureTransfectionBiochemistryGeneticsRNA Interference and Gene DeliveryAdvanced biosensing and bioanalysis techniquesAnimal Genetics and Reproduction